GlassScriptPhysician profile
Anna L Heck
NPI 1285922138
$5,828.56
in general payments reported to CMS, 2019-2025
31 companies · $763 in 2025
The $763 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $905 · 2022: $1,309 · 2023: $1,185 · 2024: $1,667 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.65 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $755.40 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $606.84 | 2021-2025 | Tremfya |
| Abbvie INC. | $534.78 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $455.48 | 2021-2025 | Ilumya |
| Genzyme Corporation | $346.99 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $346.63 | 2021-2025 | |
| Lilly USA, LLC | $252.13 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $243.01 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $238.88 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $213.34 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $199.23 | 2022-2024 | Oracea, Aklief |
| E.R. Squibb & Sons, L.L.C. | $138.14 | 2022-2025 | Sotyktu |
| Ucb, INC. | $132.98 | 2023-2024 | Bimzelx, Cimzia |
| Alnylam Pharmaceuticals INC. | $121.84 | 2024 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $120.65 | 2025 | Airsupra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $119.28 | 2024 | Watchman Access System |
| Biofrontera INC. | $114.32 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Esperion Therapeutics, INC. | $103.45 | 2021 | |
| Amgen INC. | $103.11 | 2024-2025 | Otezla, Otezla |
| Intuitive Surgical, INC. | $96.57 | 2023 | Da Vinci Surgical System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.15 | 2022 | |
| Biogen, INC. | $96.10 | 2021 | |
| Epi Health, LLC | $95.73 | 2022 | |
| Pfizer INC. | $73.37 | 2021-2025 | |
| Incyte Corporation | $53.95 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.01 | 2022 | |
| Cipher Pharmaceuticals US LLC | $28.65 | 2025 | Natroba, Spinosad |
| Leo Pharma INC. | $26.20 | 2022 | |
| Merz North America, INC. | $22.30 | 2021 | |
| Almirall LLC | $22.05 | 2021 | |
| Journey Medical Corporation | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Heck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.